Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.
Historical daily share price chart and data for Cassava Sciences since 2020 adjusted for splits. The latest closing stock price for Cassava Sciences as of June 19, 2020 is 2.64. The all-time high Cassava Sciences stock closing price was 9.65 on January 03, 2020.; The Cassava Sciences 52-week high stock price is 10.95, which is 314.8% above the current share price.
Cassava Sciences's stock reverse split on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 9th 2017. An investor that had 100 shares of Cassava Sciences stock prior to the reverse split would have 14 shares after the split.
You can buy and sell Cassava Sciences (SAVA) stock and options and many more commission-free on Robinhood with real-time quotes, market data, and relevant news. 4,340 people own Cassava Sciences on Robinhood on June 22, 2020.
Cassava Sciences, Inc. Common Stock (SAVA) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.
Find the latest Cassava Sciences, Inc. (SAVA) stock quote, history, news and other vital information to help you with your stock trading and investing.
Cassava Sciences, Inc. (SAVA - Free Report) was a big mover last session, as the company saw its shares rise more than 8% on the day.The move came on solid volume too with far more shares changing.
Stock analysis for Cassava Sciences Inc (SAVA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
View detailed financial information, real-time news, videos, quotes and analysis on Cassava Sciences Inc. (NASDAQ:SAVA). Explore commentary on Cassava Sciences Inc. and hear what the experts at.
Find real-time SAVA - Cassava Sciences Inc stock quotes, company profile, news and forecasts from CNN Business.
The current RSI for SAVA stock in for the last two-week period is set at 75.82, with the RSI for the last a single of trading hit 79.66, and the three-weeks RSI is set at 69.93 for Cassava Sciences Inc. (SAVA). The present Moving Average for the last 50 days of trading for this stock 5.53, while it was recorded at 8.04 for the last single week of trading, and 3.75 for the last 200 days.
Check out our SAVA stock analysis, current SAVA quote, charts, and historical prices for Cassava Sciences Inc stock.
Get Cassava Sciences Inc (SAVA:NASDAQ) real-time stock quotes, news and financial information from CNBC.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. It is also developing an experimental biomarker diagnostic PTI-125 to detect Alzheimer's disease with the help of a blood test. More. News Headlines for Cassava Sciences Inc. Cassava Sciences Announces Presentation at the Jefferies.
View Cassava Sciences Inc. (SAVA) stock price and volume charts for most recent trading day, 5-day, 1-month and longer monthly and yearly timeframes. Includes settings for advanced statistics, like moving average and relative strength index.
In depth view into SAVA (Cassava Sciences) stock including the latest price, news, dividend history, earnings information and financials.
The latest Cassava Sciences Inc USD0.001 share price. View recent trades and share price information for Cassava Sciences Inc USD0.001.
Cassava Sciences Added To Russell Indexes And Provides Phase 2b Study Update Benzinga Newsdesk Tue, 16 Jun 2020 08:16:01 -0400; 77 Biggest Movers From Yesterday Lisa Levin Fri, 05 Jun 2020 05:18.
Cassava Sciences, Inc., formerly Pain Therapeutics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing drug for the treatment of nervous system disorders. The Company is ocused on the ea rly detection and treatment of neurodegenerative diseases, such as Alzheimer’s. Its drug candidate, PTI-125, is a.